topotecan has been researched along with Kidney Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ankenbruck, N; Connelly, CM; Deiters, A; Gardner, L; Naro, Y; Thomas, M; Tivon, Y | 1 |
| Funke, S; Gasis, M; Hanenberg, H; Heikaus, S; Liverts, A; Mahotka, C; Nitsche, V; Schirmacher, P; Toth, C; Wiek, C; Zlachevska, V | 1 |
| Bhattacharya, A; Chintala, S; Durrani, FA; Rustum, YM | 1 |
| Acha, T; Bergeron, C; Catania, S; Graf, N; Howell, L; Mavinkurve-Groothuis, AM; Pritchard-Jones, KL; Spreafico, F; Tytgat, GA; van den Heuvel-Eibrink, MM; van Tinteren, H; Vujanic, G | 1 |
| Bjarnason, GA; Bocci, G; Di Desidero, T; Jedeszko, C; Kerbel, RS; Lee, CR; Man, S; Paez-Ribes, M; Xu, P | 1 |
| Gabbert, HE; Heikaus, S; Mahotka, C; Pejin, I; Ramp, U | 1 |
| Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G | 1 |
| Asano, T; Horiguchi, A; Ito, K; Sato, A; Sumitomo, M | 1 |
| Fleck, C; Hilger, R; Jurkutat, S; Karge, E; Merkel, U; Schimske, A; Schubert, J | 1 |
| Adams, D; Guillot, A; Homans, AC; Iacono, LC; McCune, JS; Stewart, CF | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Dal Bianco, M; De Zorzi, L; Pastorelli, D; Salmaso, F; Zovato, S; Zustovich, F | 1 |
| Asano, T; Hayakawa, M; Ito, K; Sato, A; Sumitomo, M | 2 |
| Casliskan, E; Gabbert, HE; Heikaus, S; Mahotka, C; Ramp, U | 1 |
| Alvarado, C; Billups, CA; Chintagumpala, M; Coppes, MJ; Daw, NC; Dome, JS; Freeman, BB; Grant, R; Hoffer, FA; Metzger, ML; Mullen, EA; Stewart, CF; Wu, J | 1 |
| Alders, M; Cransberg, K; Loos, WJ; Lugtenberg, RT; van den Heuvel-Eibrink, MM; Wagner, A | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Ilson, DH; Law, TM; Motzer, RJ | 1 |
| Déjosez, M; Gabbert, HE; Gerharz, CD; Krieg, A; Mahotka, C; Ramp, U; Walczak, H | 1 |
| Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ | 1 |
| Huang, J; Kandel, JJ; Kim, E; Manley, C; Middlesworth, W; Moore, JT; O'Toole, K; Soffer, SZ; Stolar, C; Yamashiro, DJ; Yokoi, A | 1 |
1 review(s) available for topotecan and Kidney Neoplasms
| Article | Year |
|---|---|
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
6 trial(s) available for topotecan and Kidney Neoplasms
| Article | Year |
|---|---|
Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Wilms Tumor | 2015 |
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
Topics: Area Under Curve; Child; Child, Preschool; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Wilms Tumor | 2007 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Phase II trial of topotecan in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan | 1994 |
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
15 other study(ies) available for topotecan and Kidney Neoplasms
| Article | Year |
|---|---|
Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; MicroRNAs; Small Molecule Libraries; Topotecan | 2018 |
The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Topics: Active Transport, Cell Nucleus; Aniline Compounds; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mitochondria; Molecular Targeted Therapy; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Topotecan; Tumor Suppressor Protein p53 | 2017 |
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mice, Nude; MicroRNAs; Selenocysteine; Selenomethionine; Topotecan | 2018 |
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Maximum Tolerated Dose; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Survival Analysis; Topotecan; Xenograft Model Antitumor Assays | 2015 |
PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.
Topics: Apoptosis; Carcinoma, Renal Cell; Carrier Proteins; Caspase 2; Cell Line, Tumor; CRADD Signaling Adaptor Protein; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Topotecan; Tumor Cells, Cultured; Up-Regulation | 2010 |
Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Melphalan; Nephrectomy; Topotecan; Wilms Tumor; Young Adult | 2011 |
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Kidney Neoplasms; Topotecan; Vorinostat | 2011 |
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carcinoma, Renal Cell; Cisplatin; Dexamethasone; Epidermal Growth Factor; Female; Glucocorticoids; Humans; Kidney; Kidney Neoplasms; Methotrexate; Quinazolines; Rats; Rats, Wistar; Thiophenes; Topotecan; Triiodothyronine | 2002 |
Topotecan disposition in an anephric child.
Topics: Antineoplastic Agents; Child; Cyclophosphamide; Enzyme Inhibitors; Humans; Kidney Neoplasms; Male; Renal Dialysis; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan; Wilms Tumor | 2004 |
Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Liposomes; Microtubule-Associated Proteins; Neoplasm Proteins; RNA, Small Interfering; Survivin; Topotecan; Transfection | 2007 |
Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Oligonucleotide Array Sequence Analysis; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transcriptional Activation | 2007 |
Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; RNA, Small Interfering; Survivin; Topotecan; Transfection | 2008 |
Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dactinomycin; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Exons; Female; Frameshift Mutation; Genes, Wilms Tumor; Germ-Line Mutation; Humans; Infant; Kidney Neoplasms; Loss of Heterozygosity; Metabolic Clearance Rate; Nephrectomy; Peritoneal Dialysis; Polymorphism, Single Nucleotide; RNA Splice Sites; Sequence Analysis, DNA; Topotecan; Vincristine; Wilms Tumor | 2008 |
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Enzyme Inhibitors; Genes, p53; Humans; Kidney Neoplasms; Membrane Glycoproteins; Mutation; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Up-Regulation | 2000 |
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Disease Models, Animal; Endothelial Growth Factors; In Situ Nick-End Labeling; Injections, Intraperitoneal; Kidney Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Reference Values; Sensitivity and Specificity; Survival Rate; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wilms Tumor | 2001 |